Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Stem cell expansion - Platelet-derived growth factor enhances ex vivo expansion of megakaryocytic progenitors from human cord blood
Autore:
Su, RJ; Li, K; Yang, M; Zhang, XB; Tsang, KS; Fok, TF; Li, CK; Yuen, PMP;
Indirizzi:
Chinese Univ Hong Kong, Prince Wales Hosp, Dept Paediat, Sha Tin, Hong Kong, Peoples R China Chinese Univ Hong Kong Sha Tin Hong Kong Peoples R China Peoples R China Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anat & Cellular Pathol, Sha Tin, Hong Kong, Peoples R China Chinese Univ Hong Kong Sha Tin Hong KongPeoples R China Peoples R China
Titolo Testata:
BONE MARROW TRANSPLANTATION
fascicolo: 10, volume: 27, anno: 2001,
pagine: 1075 - 1080
SICI:
0268-3369(200105)27:10<1075:SCE-PG>2.0.ZU;2-#
Fonte:
ISI
Lingua:
ENG
Soggetto:
HIGH-DOSE CHEMOTHERAPY; PERIPHERAL-BLOOD; BONE-MARROW; BREAST-CANCER; HEMATOPOIETIC PROGENITORS; CD34(+) CELLS; THROMBOPOIETIN; INVITRO; LIGAND; PROLIFERATION;
Keywords:
platelet-derived growth factor; ex vivo expansion; megakaryocytic progenitors; ploidy;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
33
Recensione:
Indirizzi per estratti:
Indirizzo: Li, K Chinese Univ Hong Kong, Prince Wales Hosp, Dept Paediat, 6th Fl, ShaTin, Hong Kong, Peoples R China Chinese Univ Hong Kong 6th Fl Sha Tin HongKong Peoples R China ina
Citazione:
R.J. Su et al., "Stem cell expansion - Platelet-derived growth factor enhances ex vivo expansion of megakaryocytic progenitors from human cord blood", BONE MAR TR, 27(10), 2001, pp. 1075-1080

Abstract

Infusion of ex vivo expanded megakaryocytic (MK) progenitor cells is a strategy for shortening the duration of thrombocytopenia after haematopoietic stem cell transplantation. The cell dose after expansion has emerged as a critical factor for achieving the desired clinical outcomes. This study aimed to establish efficient conditions for the expansion of the MK lineage from enriched CD34(+) cells of umbilical cord blood and to investigate the effect of platelet-derived growth factor (PDGF) in this system. Our results demonstrated that thrombopoietin (TPO) alone produced a high proportion of CD61(+)CD41(+) cells but a low total cell count and high cell death, resulting in an inferior expansion. The addition of interleukin-1 beta (IL-1 beta),Flt-3 ligand (Flt-3L) and to a lesser extent IL-3 improved the expansion outcome. The treatment groups with three to five cytokines produced efficient expansions of CFU-MK up to 400-fold with the highest yield observed in the presence of TPO, IL-1 beta, IL-3, IL-6 and Flt-3L, CD34(+) cells were expanded by five to 22-fold. PDGF improved the expansion of all cell types with CD61(+)CD41(+) cells, CFU-MK and CD34(+) cells increased by 101%, 134% and 70%, respectively. On day 14, the CD61(+) population consisted of diploid(86.5%), tetraploid (11.8%) and polyploid (8N-32N; 1.69%) cells. Their levels were not affected by PDGF, TPO, IL-1 beta, 1L-3, IL-6, Flt-3L and PDGF represented an effective cytokine combination for expanding MK progenitors while maintaining a moderate increase of CD34(+) cells. This study showed, for the first time, that PDGF enhanced the ex vivo expansion of the MK lineage, without promoting their in vitro maturation. PDGF might be a suitable growth factor to improve the ex vivo expansion of MK progenitors for clinical applications.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 31/03/20 alle ore 19:40:58